Late relapsing childhood lymphoblastic leukemia.
Childhood lymphoblastic leukemia (ALL) is usually assumed to have been permanently eradicated in patients in long-term remission, but occasionally can recur after many years. To learn more about the problem, we studied a group of children whose leukemia had been in remission for 10 or more years before relapse and tried to determine whether they had true recurrences or second malignancies. We studied children treated on Medical Research Council ALL protocols between 1970 and 1984 and followed up by the Clinical Trial Service Unit in Oxford. Detailed clinical and laboratory data was collected from the centers concerned on all who were reported to have had a recurrence of their leukemia after 10 or more years from the time of achieving first complete remission (CR1). To prove that the relapse was a true recurrence rather than a second or secondary leukemia, DNA extracted from archived marrow smears was subjected to polymerase chain reaction (PCR) analysis for the presence of an identical Ig heavy chain (IgH) or T-cell receptor (TCR) gene rearrangement at initial diagnosis and subsequent relapse. A total of 1,134 of 2,746 children had survived 10 years or more (range, 10 to 24 years) in CR1 and of those, 12 (approximately 1%) had subsequently relapsed. Relapse blast cells were shown to express the common ALL antigen (CD 10) in all cases and an identical clonal IgH or TCR gene rearrangement was found on PCR analysis of DNA from diagnosis and relapse in all eight cases where DNA extraction was successful. A further program of therapy was successful in inducing a second CR in all patients, four of whom have succumbed to a second relapse after 12 to 27 months. The remaining eight are in continuing CR2 at a follow-up of 12 to 108 months (median, 52) from relapse. Although the risk of relapse of childhood ALL after 10 years in remission appears to be small (around 1%), it persists. This raises questions about how blasts can survive quiescent for so long and when we can truly be confident of cure, if ever.
Vora
A
A
Molecular Haematology Unit, Children's and Royal Hallamshire Hospital, Sheffield, UK. A.J.Vora@Sheffield.ac.uk
Frost
L
L
Goodeve
A
A
Wilson
G
G
Ireland
R M
RM
Lilleyman
J
J
Eden
T
T
Peake
I
I
Richards
S
S
D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002999:Clone Cells / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D004739:England / Q000453:epidemiology; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D015329:Gene Rearrangement, T-Lymphocyte; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis; D018365:Neoplasm, Residual; D016609:Neoplasms, Second Primary / Q000175:diagnosis; D014411:Neoplastic Stem Cells / Q000473:pathology; D015260:Neprilysin / Q000032:analysis; D016133:Polymerase Chain Reaction; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D017741:Survivors; D013997:Time Factors; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D015260:Neprilysin